Related Experiment Video
Updated: Aug 18, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
[Our experience with patients operated after neoadjuvant therapy]
Miklós Juhász1, Gábor Egri, Csaba Váradi
1Fovárosi Onkormányzat Bajcsy-Zsilinszky Kórház es Rendelointézet Altalános Sebészet, Mellkassebészeti es Ersebészeti Osztály, Budapest. jumidr@axelero.hu
Abstract:
The authors performed thoracotomies on 47 patients because of NSCLC between 1 January 2000 and 31 December 2003. All patients had neoadjuvant therapy which was indicated by IIIA stage NSCLC with N2 nodal status. After the neoadjuvant therapy almost all tumors (92.7%) became resectable. The combinations of therapy types, the operations type and the surgical complications are analysed. Long term outcome proves, that multimodal therapy of NSCLC (in IIIA stage) is an effective treatment method.
